NCT03541720 is a EARLY_PHASE1 clinical trial of 18F-DA in Neuroblastoma, sponsored by St. Jude Children's Research Hospital.

Who is sponsoring NCT03541720?

NCT03541720 is sponsored by St. Jude Children's Research Hospital.

What drugs are being tested in NCT03541720?

Interventions in NCT03541720: 18F-DA.

What condition does NCT03541720 study?

NCT03541720 studies Neuroblastoma, Pheochromocytoma.

Is NCT03541720 still recruiting?

NCT03541720 is currently active, enrolled. Last updated 3 December 2025.

Last reviewed 2025-12-03 · How we verify

NCT03541720

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

Active, enrolled EARLY_PHASE1 Last updated 3 December 2025

What this trial tests

EARLY_PHASE1 trial testing 18F-DA in Neuroblastoma in 13 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 April 2019

Primary endpoint
1 January 2027

1 July 2028

Quick facts

Lead sponsor	St. Jude Children's Research Hospital
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	13
Start date	30 April 2019
Primary completion	1 January 2027
Estimated completion	1 July 2028
Sites	1 location across United States

Drugs / interventions tested

18F-DA — full drug profile →

Conditions studied

Neuroblastoma — all drugs for Neuroblastoma →
Pheochromocytoma — all drugs for Pheochromocytoma →

Sponsor

St. Jude Children's Research Hospital

Who can join

1 and older, any sex, with Neuroblastoma or Pheochromocytoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PET (positron emission tomography) scans combined with a radioactive tracer will be used to identify and analyze tumors. Currently, the most common tracer used to analyze neuroblastoma tumors is called 123I-mIBG. However, the picture it provides is not always clear enough to see the very small areas of the disease. 18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma. With this research study, the investigators plan to meet the following goals: * Investigate to see if 18F-DA is safe to administer to pediatric patients with known or suspected neuroblastoma or pheochromocytoma * Examine where in the body 18F-DA goes. * Obtain information comparing 18F-DA to 123I-mIBG to see if 18F-DA could replace 123I-mIBG in the future. About 20 people, with known or suspected neuroblastoma or pheochromocytoma, will take part in this Pilot study at St. Jude.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.
Stauff E, Karimi H, Kecskemethy HH, Shaffer TH, et al · · 2025 · PMID 41282032 · DOI 10.3389/fmed.2025.1658588

Verify or expand the search:

Other recruiting trials for Neuroblastoma

Currently open trials in the same condition.

NCT07399821 — An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma · Phase 1, PHASE2 · recruiting
NCT06995872 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra · Phase 1 · recruiting
NCT06942039 — Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation · EARLY_PHASE1 · recruiting
NCT07067346 — Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma · EARLY_PHASE1 · recruiting
NCT07027748 — Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or R · Phase 1 · recruiting

Other St. Jude Children's Research Hospital trials

Trials by the same sponsor.

NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03541720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing